Insight

Reference

·

Supporting source

·Preview

Cosmetic, aesthetic share of medical-tourism revenue

~26%

As ofFY2024·Sources3·Supporting

Cosmetic, aesthetic leads the procedure mix at ~26%, ahead of cardiac (~22%), orthopedic (~16%), oncology (~14%), fertility, IVF (~10%) and dental, ophthalmology, other (~12%).

Compare plans →

Figure in context

Cosmetic, aesthetic leads the procedure mix at ~26%, ahead of cardiac (~22%), orthopedic (~16%), oncology (~14%), fertility, IVF (~10%) and dental, ophthalmology, other (~12%).

Cosmetic, aesthetic leads the procedure mix at ~26%, ahead of cardiac (~22%), orthopedic (~16%), oncology (~14%), fertility, IVF (~10%) and dental, ophthalmology, other (~12%).

Time scope

FY2024

Source basis

Supporting source

Interpretation notes

What this tells you

Cosmetic, aesthetic leads the procedure mix at ~26%, ahead of cardiac (~22%), orthopedic (~16%), oncology (~14%), fertility, IVF (~10%) and dental, ophthalmology, other (~12%).

What not to do with it

Use the linked report for interpretation and keep basis differences explicit.

Related figures

Adjacent numbers that add context without drowning the value.

FY2025
~580k/year

Thai medical tourist annual volume

TAT, MoPH HSS, Economist Impact APAC Index, The Nation Thailand

FY2025
THB 220B

Thai medical-tourism direct receipts

TAT, MoPH, Economist Impact, The Nation Thailand

FY2024
USD 8-15k

Thai cardiac bypass pricing vs US

IMTJ pricing benchmarks, Patients Beyond Borders

FY2024
60+

Thai JCI-accredited hospitals

JCI accreditation registry, Thai Hospital Association

FY2024
~3-4M

2024 medical-tourism visits

Tourism Authority of Thailand, Economist Impact APAC Index

2026 Q1
60+

JCI-accredited hospitals

Joint Commission International

Report context

Thailand Medical Tourism Pricing & Economics Deep Dive

Deep-dive into Thailand's medical tourism pricing, payer mix, cross-border patient flows. 3-4M medical tourists/yr generating USD 1.5-2B receipts. Listed hospital operators: BDMS (SET: BDMS — Bumrungrad, Samitivej, BPH), Bangkok Chain Hospital (SET: BCH), Chularat (SET: CHG), Principal Healthcare (SET: PRINC), Thonburi Healthcare (SET: THG), Praram 9 (SET: PR9), plus Bumrungrad International direct. Procedure pricing: cosmetic USD 1.5-4k (vs USD 6-15k US), cardiac bypass USD 8-15k (vs USD 70-100k US), IVF USD 4-6k/cycle (vs USD 15-20k US). Cross-border flows: GCC (~30%) premium cardiac, oncology, rehab; CLMV (~24%) emergency, elective; China (~18%) cosmetic, anti-aging, reproductive; USA, Europe, Australia (~16%) cost-sensitive cardiac, orthopedic, cosmetic. Payers: self-pay ~70%, international insurers (Cigna Global, Bupa Global, GeoBlue, AXA Global), government contracts, employer plans. Thai Medical Council, MoPH regulate; TAT markets.

Open report →

Atlas actors in this figure's reports

Profiles covered in the report that cite this number.

Bangkok Chain Hospital

Mid-market listed hospital operator — Kasemrad brand across 15+ hospitals; SSS, UCS contract-heavy franchise.

Bangkok Dusit Medical Services

Thailand's largest listed hospital group — 50+ hospitals across six brand families; >THB 110B FY2024 revenue.

Bumrungrad Hospital

Thailand's medical-tourism flagship — first Asian hospital JCI-accredited (2002); >60% international-patient revenue mix.

Chularat Hospital

Eastern Thailand, EEC industrial-estate hospital specialist — SSS, corporate-contract franchise; FY2024 revenue ~THB 7B.

Praram 9 Hospital

Listed specialist-led Bangkok hospital; kidney-transplant, cardiac-specialty tertiary care; FY2024 revenue ~THB 4-5B.

Principal Capital / Princ Holdings

Listed hospital chain operator; Princ-branded upcountry hospital network (Suvarnabhumi, Chiang Mai, Phitsanulok); FY2024 revenue ~THB 4-5B.

Cosmetic, aesthetic share of medical-tourism revenue · Insight